Thumbnail Image
Item

Retrospective study investigating naloxone prescribing and cost in US Medicaid and Medicare patients

Manko, Christopher D.
; 
Ahmed, Mohamed S.
; 
Harrison, Lavinia R.
; 
Kodavatiganti, Srivastava A.
; 
Lugo, Noelia
; 
Konadu, Jason Osei
; 
Khan, Farrin
; 
Massari, Carrie A.
; 
Sealey, Tenisha K.
; 
Addison, Maame Efua
... show 4 more
Citations
Altmetric:
Genre
Journal article
Date
2024-05-01
Advisor
Committee member
Group
Department
Subject
Clinical pharmacology
 Epidemiology
 Public health
Permanent link to this record
https://scholarshare.temple.edu/handle/20.500.12613/12046
Collections
Faculty/Researcher Works
Show all metadata
Files
Thumbnail Image
Konadu-JournalArticle-2024-05.pdf
Adobe PDF, 2.31 MB
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.1136/bmjopen-2023-078592
Abstract
Background Opioid overdoses in the USA have increased to unprecedented levels. Administration of the opioid antagonist naloxone can prevent overdoses. Objective This study was conducted to reveal the pharmacoepidemiologic patterns in naloxone prescribing to Medicaid patients from 2018 to 2021 as well as Medicare in 2019. Design Observational pharmacoepidemiologic study Setting US Medicare and Medicaid naloxone claims Intervention The Medicaid State Drug Utilisation Data File was utilised to extract information on the number of prescriptions and the amount prescribed of naloxone at a national and state level. The Medicare Provider Utilisation and Payment was also utilised to analyse prescription data from 2019. Outcome measures States with naloxone prescription rates that were outliers of quartile analysis were noted. Results The number of generic naloxone prescriptions per 100 000 Medicaid enrollees decreased by 5.3%, whereas brand naloxone prescriptions increased by 245.1% from 2018 to 2021. There was a 33.1-fold difference in prescriptions between the highest (New Mexico=1809.5) and lowest (South Dakota=54.6) states in 2019. Medicare saw a 30.4-fold difference in prescriptions between the highest (New Mexico) and lowest states (also South Dakota) after correcting per 100 000 enrollees. Conclusions This pronounced increase in the number of naloxone prescriptions to Medicaid patients from 2018 to 2021 indicates a national response to this widespread public health emergency. Further research into the origins of the pronounced state-level disparities is warranted.
Description
Citation
Manko CD, Ahmed MS, Harrison LR, et alRetrospective study investigating naloxone prescribing and cost in US Medicaid and Medicare patientsBMJ Open 2024;14:e078592. doi: 10.1136/bmjopen-2023-078592
Citation to related work
BMJ
Has part
BMJ Open, Vol. 14, Iss. 5
ADA compliance
Embedded videos
License
Attribution-NonCommercial CC BY-NC
cbn